BioSpace News Archive

The Asia Pacific mHealth market is expected to observe impressive growth over the forecast period due to the increasing prevalence of chronic diseases, especially among geriatric population.

Since the introduction of medical imaging devices in the 20th century, the utilization of medical imaging technology has been gaining ground in Europe, aided by the enhanced healthcare policies and growing availability of high-quality medical equipment.

The North America autoimmune disease diagnostics market outlook has been receiving significant impetus from the growing adoption rate of lab automation technologies.

The burgeoning number of peripheral and coronary artery surgical procedures across the world is a key factor expected to accelerate the stents market over the forecast period.

Atlas Antibodies AB has signed an agreement to acquire UK company HistoCyte Laboratories Ltd. HistoCyte Laboratories’ portfolio of innovative cell line materials provides control of immunohistochemical assays used in the diagnosis of cancers.

- Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo - Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks

Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.

CAGE Bio Inc., an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced the closing of a $7.2 million over-subscribed Series A financing.

Celera Motion, a leader in precision motion component and sub-system solutions and a business unit of Novanta Corporation announces the addition of Capitan Series to their line of premium performance Ingenia servo drives.

Maxwell Biosciences develops antiviral drugs, designed to be Zero-Day Therapeutics, which have been shown in preclinical studies to destroy a broad spectrum of viruses including rapidly evolving Coronavirus strains, announced the appointment of prominent New York University faculty member Kent Kirshenbaum, Ph.D., as the company’s Chief Scientific Officer.